A Randomised Controlled Trial Comparing the Pharmacokinetics and Tolerability of the Proposed Adalimumab Biosimilar MSB11022 Delivered via Autoinjector and Pre-filled Syringe in Healthy Subjects

[1]  Pantelis K. Vlachos,et al.  AURIEL‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis , 2019, The British journal of dermatology.

[2]  P. Vlachos,et al.  Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis , 2019, Clinical Rheumatology.

[3]  L. Fraenkel,et al.  Patient preferences for rheumatoid arthritis treatment , 2019, Current opinion in rheumatology.

[4]  J. Ghil,et al.  Usability and safety of SB5 (an adalimumab biosimilar) prefilled syringe and autoinjector in patients with rheumatoid arthritis , 2019, Current medical research and opinion.

[5]  L. Kristensen,et al.  A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience , 2019, Drug delivery.

[6]  N. Maniadakis,et al.  A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences , 2018, Advances in Therapy.

[7]  B. Liedert,et al.  Similar Pharmacokinetics of the Adalimumab (Humira®) Biosimilar BI 695501 Whether Administered via Subcutaneous Autoinjector or Prefilled Syringe (VOLTAIRE®-AI and VOLTAIRE®-TAI): Phase 1, Randomized, Open-Label, Parallel-Group Trials , 2018, Rheumatology and Therapy.

[8]  A. Niewiarowski,et al.  Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects , 2017, British journal of clinical pharmacology.

[9]  D. Rubin,et al.  Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis. , 2017, Journal of managed care & specialty pharmacy.

[10]  M. Rossi,et al.  Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira® , 2016, mAbs.

[11]  P. Vlachos,et al.  Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira® in healthy subjects , 2016, British journal of clinical pharmacology.

[12]  Uwe Pichlmeier,et al.  Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience , 2014, Patient preference and adherence.

[13]  P. Laurent,et al.  Results of a human factors experiment of the usability and patient acceptance of a new autoinjector in patients with rheumatoid arthritis , 2014, Patient preference and adherence.

[14]  J. Borrás-Blasco,et al.  Acceptability of switching adalimumab from a prefilled syringe to an autoinjection pen , 2010, Expert opinion on biological therapy.

[15]  S. Cohen,et al.  Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. , 2006, Clinical therapeutics.